Gilead Inhalation Antibiotic For Cystic Fibrosis Successful In Second Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans to submit aztreonam in the second half of 2007.
You may also be interested in...
Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports
Convenience and tolerability benefits could position aztreonam lysine as best-in-class.
Gilead’s Cystic Fibrosis Drug Looks Good Long-Term, Firm Reports
Convenience and tolerability benefits could position aztreonam lysine as best-in-class.
Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.